Alnylam, Isis Announce Notice of Allowance for RNAi-Related Patent Application | GenomeWeb

Alnylam Pharmaceuticals and Isis Pharmaceuticals said this week that the US Patent and Trademark Office has issued a notice of allowance for a US patent application covering chemically modified RNA-containing therapeutics.

The application, No. 20020165189, is entitled, "Oligoribonucleotides and Ribonucleases for Cleaving RNA," and specifically claims "oligoribonucleotides and oligoribonucleosides … [with] subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase," according to its abstract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.